Polarean Imaging shares up 5% after pharma deal; bank repeats 'buy'
Published: 06:10 10 Mar 2025 EDT
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) shares climbed 5% in early trading after securing a major deal to expand its Xenon MRI technology into pharmaceutical research.
A top global pharmaceutical company has selected Polarean’s imaging services for a multi-centre clinical trial, which will evaluate an investigational lung treatment.
The trial will use Xenon MRI to analyse how the drug affects lung function, offering detailed insights into ventilation and gas exchange.
This marks a significant step for Polarean, which has been working to establish a dedicated imaging platform for pharmaceutical research.
Partnering with VIDA Diagnostics, the company aims to streamline drug trials by ensuring high-quality imaging, potentially reducing the number of patients needed and speeding up the approval process.
"Xenon MRI has multiple potential applications and supporting clinical trials is a logical addition to its clinical uses, and we believe could generate meaningful revenues over time," said American bank Stifel repeating its 'buy' recommendation.
In early trading, the stock was up 0.06p at 1.28p.
